BACKGROUND/AIM: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course. PATIENTS AND METHODS: We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis. RESULTS: Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment. CONCLUSION: These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones. Copyright
BACKGROUND/AIM: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course. PATIENTS AND METHODS: We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis. RESULTS: Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment. CONCLUSION: These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones. Copyright
Authors: Lian Li; Yachao Li; Chieh-Hsiang Yang; D Christopher Radford; Jiawei Wang; Margit Janát-Amsbury; Jindřich Kopeček; Jiyuan Yang Journal: Adv Funct Mater Date: 2020-02-03 Impact factor: 18.808
Authors: Laura C Kennedy; Jun Lu; Sydney Kuehn; Arturo B Ramirez; Edward Lo; Yao Sun; Lance U'Ren; Laura Q M Chow; Zhengjia Chen; Petros Grivas; Eric P Kaldjian; Vijayakrishna K Gadi Journal: Target Oncol Date: 2022-06-13 Impact factor: 4.864